Utilizing RNAscope in the clinic to handle complex analysis. RNAscope is rapidly becoming a solution for understanding complex biomarker challenges. The benefits and awareness of image analysis in the space of pathology have been widely discussed and rapidly growing....
Events
UPCOMING EVENTS
- Spatial Biology for Drug Development Summit 2023 | October 11-13, Boston, MA (Exhibitor)
- Society for Immunotherapy of Cancer (SITC) Annual Meeting | November 3-5, San Diego, CA (Booth #716)
- American Society for Hematology (ASH) Annual Meeting & Exposition | December 9-12, San Diego, CA (Booth #3349)
Precision Patient Care: Seamless Optimization of Diagnoses, Companion Testing and Therapy Design
Technology Leads the Way to Precision Patient Care Digital transformation comes in many flavors. In pathology, it can be as simple as merely scanning pathology slides into whole slide images. However, it can also represent end-to-end digital pathology workflow...
Pathology Visions 2021
Pathology Visions 2021October 17-19, 2021Digital Pathology: The Future is Here is the theme of this year’s Digital Pathology Association annual conference, Pathology Visions 2021. #PathVisions21 featured a poster from Flagship’s CCO Meredith James on a novel approach...
Webcast – TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology
View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
SITC 2021
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Webcast Recording: Tissue-Based CDx Development and Image Analysis in a Regulated Space
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Paige and Flagship Biosciences Announce Partnership to Expand Access to Immuno-Oncology Biomarker Analysis Tools
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue typesNEW YORK, NY and BROOMFIELD, CO — February 17, 2022 — Paige, the global leader in AI-based diagnostic software in pathology, and Flagship...
Flagship Biosciences Listed Among 2022 Colorado Best Small Companies to Work For
Flagship Biosciences Earns Recognition as One of the Best Small Companies to Work For in ColoradoBroomfield, CO — January 5, 2022 — Today, Built In announced that Flagship Biosciences was honored in its 2022 Best Places To Work Awards. Specifically, Flagship...
Recognizing women leaders in biotechnology
The COVID-19 pandemic has highlighted the important need for cutting-edge life science research and technology to improve health outcomes. The Healthcare Technology Report recently announced, “The Top 25 Women Leaders in Biotechnology of 2021”, which is comprised of...
PUBLICATIONS/POSTERS
Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation (Poster No. 433 #AACR2021 in partnership with Leap Therapeutics)
Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study, we demonstrate an approach for clinically validating a RNAscope chromogenic in-situ hybridization...
A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to the check point inhibitor drug pembrolizumab. However, interpretation of the PD-L1 (22C3) immunohistochemistry...
Characterizing the Heterogeneity of CD8 Inflammation in Biopsied Tumor Tissues Using Novel Image Analysis Techniques (Poster No. 3137 #AACR2021 in partnership with Scholar Rock)
Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor samples Measuring CD8 expression within tumor nests rather than averaging across a whole tissue section...